Rentokil Initial price target lowered to 450 GBp from 480 GBp at Morgan Stanley
- Price Target Adjustment: Morgan Stanley has reduced its price target for Rentokil Initial from 480 GBp to 450 GBp.
- Rating Status: The firm maintains an Equal Weight rating on the shares of Rentokil Initial.
Trade with 70% Backtested Accuracy
Analyst Views on RTO
About RTO
About the author
Reasons to Consider Rentokil Initial (RTO) as a New Investment Opportunity
Zacks Rank Upgrade: Rentokil Initial PLC has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which could lead to increased stock prices.
Earnings Estimate Revisions: The Zacks rating system emphasizes the importance of earnings estimate revisions, showing a strong correlation with near-term stock movements, making Rentokil a solid candidate for potential market-beating returns.
Analyst Consensus: Over the past three months, the Zacks Consensus Estimate for Rentokil has increased by 0.3%, reflecting analysts' growing confidence in the company's earnings potential.
Historical Performance: The Zacks Rank system has a proven track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988, highlighting the effectiveness of tracking earnings estimates for investment decisions.
Citigroup Confirms Buy Recommendation for Rentokil Initial plc - Depositary Receipt (RTO)
Citigroup's Recommendation: On October 24, 2025, Citigroup reiterated a Buy recommendation for Rentokil Initial plc - Depositary Receipt (NYSE:RTO), despite an average one-year price target suggesting a 4.39% downside from its current price of $29.31/share.
Projected Revenue and EPS: Rentokil Initial plc is projected to have an annual revenue of $6,094 million, reflecting a 10.12% increase, with a non-GAAP EPS forecast of 0.28.
Fund Sentiment: There are 471 funds reporting positions in Rentokil Initial, with a 5.99% decrease in the number of owners over the last quarter, while total shares owned by institutions increased by 6.46% to 393,907K shares.
Shareholder Activity: Notable changes in shareholder positions include significant increases by AEPGX and OAKIX, while BLACKROCK EQUITY DIVIDEND FUND reported a decrease in shares owned, indicating varied investment strategies among major funds.
UBS Maintains Neutral Rating on Rentokil Initial plc - Depositary Receipt (RTO)
UBS Coverage and Price Forecast: UBS has reiterated a Neutral recommendation for Rentokil Initial plc - Depositary Receipt (NYSE:RTO) with an average one-year price target of $28.02/share, indicating a potential upside of 4.76% from its current price of $26.75/share.
Fund Sentiment and Institutional Holdings: There are 470 funds reporting positions in RTO, with a slight decrease in the number of owners but an increase in total shares owned by institutions by 6.46% over the last three months, reflecting a bullish outlook indicated by a put/call ratio of 0.56.
Terminix Reveals 2024's 50 U.S. Cities with the Most Rodent Infestations
Rodent Infestation Trends: The 2024 Top 50 Most Rodent-Infested U.S. Cities Report from Terminix highlights a surge in rodent infestations, driven by urban growth, warmer weather, and the movement of rodents with people, posing risks to homeowners.
Prevention Tips for Homeowners: Terminix advises homeowners to seal entry points, protect food sources, and maintain their yards to prevent rodent infestations, emphasizing that proactive measures can help avoid costly damage and health hazards.
Rentokil Initial Breaks Above 200-Day Moving Average - Bullish for RTO
Stock Performance Overview: RTO's stock has a 52-week low of $19.60 and a high of $34.07, with the last trade recorded at $24.38.
Author's Perspective Disclaimer: The opinions expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
RTO Crosses Above Key Moving Average Level
Stock Performance Overview: RTO's stock has a 52-week low of $19.60 and a high of $34.07, with the last trade recorded at $24.49.
Disclaimer on Opinions: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Reasons to Consider Rentokil Initial (RTO) as a New Investment Opportunity
Zacks Rank Upgrade: Rentokil Initial PLC has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which could lead to increased stock prices.
Earnings Estimate Revisions: The Zacks rating system emphasizes the importance of earnings estimate revisions, showing a strong correlation with near-term stock movements, making Rentokil a solid candidate for potential market-beating returns.
Analyst Consensus: Over the past three months, the Zacks Consensus Estimate for Rentokil has increased by 0.3%, reflecting analysts' growing confidence in the company's earnings potential.
Historical Performance: The Zacks Rank system has a proven track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988, highlighting the effectiveness of tracking earnings estimates for investment decisions.
Citigroup Confirms Buy Recommendation for Rentokil Initial plc - Depositary Receipt (RTO)
Citigroup's Recommendation: On October 24, 2025, Citigroup reiterated a Buy recommendation for Rentokil Initial plc - Depositary Receipt (NYSE:RTO), despite an average one-year price target suggesting a 4.39% downside from its current price of $29.31/share.
Projected Revenue and EPS: Rentokil Initial plc is projected to have an annual revenue of $6,094 million, reflecting a 10.12% increase, with a non-GAAP EPS forecast of 0.28.
Fund Sentiment: There are 471 funds reporting positions in Rentokil Initial, with a 5.99% decrease in the number of owners over the last quarter, while total shares owned by institutions increased by 6.46% to 393,907K shares.
Shareholder Activity: Notable changes in shareholder positions include significant increases by AEPGX and OAKIX, while BLACKROCK EQUITY DIVIDEND FUND reported a decrease in shares owned, indicating varied investment strategies among major funds.
UBS Maintains Neutral Rating on Rentokil Initial plc - Depositary Receipt (RTO)
UBS Coverage and Price Forecast: UBS has reiterated a Neutral recommendation for Rentokil Initial plc - Depositary Receipt (NYSE:RTO) with an average one-year price target of $28.02/share, indicating a potential upside of 4.76% from its current price of $26.75/share.
Fund Sentiment and Institutional Holdings: There are 470 funds reporting positions in RTO, with a slight decrease in the number of owners but an increase in total shares owned by institutions by 6.46% over the last three months, reflecting a bullish outlook indicated by a put/call ratio of 0.56.
Terminix Reveals 2024's 50 U.S. Cities with the Most Rodent Infestations
Rodent Infestation Trends: The 2024 Top 50 Most Rodent-Infested U.S. Cities Report from Terminix highlights a surge in rodent infestations, driven by urban growth, warmer weather, and the movement of rodents with people, posing risks to homeowners.
Prevention Tips for Homeowners: Terminix advises homeowners to seal entry points, protect food sources, and maintain their yards to prevent rodent infestations, emphasizing that proactive measures can help avoid costly damage and health hazards.
Rentokil Initial Breaks Above 200-Day Moving Average - Bullish for RTO
Stock Performance Overview: RTO's stock has a 52-week low of $19.60 and a high of $34.07, with the last trade recorded at $24.38.
Author's Perspective Disclaimer: The opinions expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
RTO Crosses Above Key Moving Average Level
Stock Performance Overview: RTO's stock has a 52-week low of $19.60 and a high of $34.07, with the last trade recorded at $24.49.
Disclaimer on Opinions: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
